Linker Information
General Information of This Linker
| Linker ID |
LIN0QQKAH
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
OXD-VA-PAB (Glu)
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C77H121N17O35S
|
|||||
| Isosmiles |
CC(C)[C@H](NC(COCC(NC1=CC=CC(C2=NN=C(O2)S(C)(=O)=O)=C1)=O)=O)C(N[C@@H](C)C(NC3=CC=C(C=C3)C(O)CC(N=N4)=CN4CC(NCC(NCC(NCC(NCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[C@@H](CCC(NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=O)C(NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=O)=O)=O)=O)=O)=O)=O)=O)=O
|
|||||
| InChI |
InChI=1S/C77H121N17O35S/c1-46(2)68(89-67(110)45-128-44-66(109)86-51-7-5-6-49(32-51)76-91-92-77(129-76)130(4,118)119)75(117)85-47(3)73(115)87-50-10-8-48(9-11-50)54(97)33-52-40-94(93-90-52)41-65(108)83-39-64(107)82-38-63(106)81-37-62(105)80-36-61(104)78-15-17-121-19-21-123-23-25-125-27-29-127-31-30-126-28-26-124-24-22-122-20-18-120-16-14-60(103)88-53(74(116)84-35-56(99)70(112)72(114)58(101)43-96)12-13-59(102)79-34-55(98)69(111)71(113)57(100)42-95/h5-11,32,40,46-47,53-58,68-72,95-101,111-114H,12-31,33-39,41-45H2,1-4H3,(H,78,104)(H,79,102)(H,80,105)(H,81,106)(H,82,107)(H,83,108)(H,84,116)(H,85,117)(H,86,109)(H,87,115)(H,88,103)(H,89,110)/t47-,53-,54?,55-,56-,57+,58+,68-,69+,70+,71+,72+/m0/s1
|
|||||
| InChIKey |
IMOHOOTYAAACEN-LYMQSKSWSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1876.966
|
Polar area
|
758.57
|
||
|
Complexity
|
.
|
xlogp Value
|
-11.2799
|
|||
|
Heavy Count
|
130
|
Rot Bonds
|
70
|
|||
|
Hbond acc
|
40
|
Hbond Donor
|
23
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
wO2024222841A1 ADC41 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 15 pM | High HER2 expression (HER2+++) | ||
| Method Description |
Cytotoxicity of ADC to SK-BR-3 cells
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
wO2024222841A1 ADC41-4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
15-25 pM
|
High HER2 expression (HER2+++) | ||
| Method Description |
Cytotoxicity of ADC to SK-BR-3 cells
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||